---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-25-000073"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:47:18.018142+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moderna Q3 net loss $200M, revenue $1.0B down 45% YoY; narrows 2025 guidance

## Summary
- Q3 revenue $1.0B (down 45% YoY); net loss $(0.51)/share vs. EPS $0.03 in Q3 2024.
- 2025 revenue range narrowed to $1.6-2.0B; GAAP opex cut by $0.7B to $5.2-5.4B.
- Year-end cash target raised by $0.5-1.0B to $6.5-7.0B; Q3-end cash $6.6B.
- COVID vaccine sales $971M; RSV mRESVIA sales $2M; mNEXSPIKE launched in US.
- Discontinues congenital CMV program after Phase 3 missed primary endpoint; norovirus study extends.

## SEC filing metadata
- accession: 0001682852-25-000073
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/0001682852-25-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/mrna-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-25-000073
- JSON: https://secwatch.observer/filing/0001682852-25-000073.json
- Plain text: https://secwatch.observer/filing/0001682852-25-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.